These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7792342)

  • 1. Diurnal variation in tardive dyskinesia.
    Hyde TM; Egan MF; Brown RJ; Weinberger DR; Kleinman JE
    Psychiatry Res; 1995 Jan; 56(1):53-7. PubMed ID: 7792342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.
    Bergen J; Kitchin R; Berry G
    Biol Psychiatry; 1992 Oct; 32(7):580-94. PubMed ID: 1360260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is tardive dyskinesia a unique disorder?
    Marsden CD
    Psychopharmacology Suppl; 1985; 2():64-71. PubMed ID: 2860661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
    Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
    Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia.
    Liddle PF; Barnes TR; Speller J; Kibel D
    Br J Psychiatry; 1993 Dec; 163():776-80. PubMed ID: 7905774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal ganglia iron in tardive dyskinesia: an MRI study.
    Elkashef AM; Egan MF; Frank JA; Hyde TM; Lewis BK; Wyatt RJ
    Biol Psychiatry; 1994 Jan; 35(1):16-21. PubMed ID: 8167198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality.
    Waddington JL; Youssef HA; Dolphin C; Kinsella A
    Arch Gen Psychiatry; 1987 Oct; 44(10):907-12. PubMed ID: 2889438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia: a review.
    Latimer PR
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S49-54. PubMed ID: 8564917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia--diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service.
    Lauterbach EC; Carter WG; Rathke KM; Thomas BH; Shillcutt SD; Vogel RL; Moore NC; Mimbs JW; Nelson WH
    Schizophr Bull; 2001; 27(4):601-13. PubMed ID: 11824487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.
    Cohen S; Khan A; Zheng Y; Chiles J
    Acta Psychiatr Scand; 1991 Mar; 83(3):234-7. PubMed ID: 1674398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
    Goff DC; Renshaw PF; Sarid-Segal O; Dreyfuss DA; Amico ET; Ciraulo DA
    Biol Psychiatry; 1993 May; 33(10):700-6. PubMed ID: 8102552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-year follow-up study of tardive dyskinesia.
    Yassa R; Nair NP
    Acta Psychiatr Scand; 1992 Oct; 86(4):262-6. PubMed ID: 1360742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study.
    Glazer WM; Morgenstern H; Doucette JT
    Br J Psychiatry; 1991 Jun; 158():822-8. PubMed ID: 1678663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum creatine phosphokinase elevations in patients with tardive dyskinesia.
    Egan MF; Dargham AA; Kirch DG; Wyatt RJ
    Br J Psychiatry; 1993 Apr; 162():551-3. PubMed ID: 8097656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia.
    Glazer WM; Hafez H
    Schizophr Res; 1990; 3(5-6):315-20. PubMed ID: 1980827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current cannabis use and tardive dyskinesia.
    Zaretsky A; Rector NA; Seeman MV; Fornazzari X
    Schizophr Res; 1993 Dec; 11(1):3-8. PubMed ID: 7905284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.